Chimerix, Inc. (CMRX): Price and Financial Metrics
CMRX Stock Summary
- CMRX's price/sales ratio is 134.77; that's higher than the P/S ratio of 96.73% of US stocks.
- With a year-over-year growth in debt of 1,335.71%, Chimerix Inc's debt growth rate surpasses 98.73% of about US stocks.
- Revenue growth over the past 12 months for Chimerix Inc comes in at -57.09%, a number that bests only 4.68% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Chimerix Inc are SRRK, GLYC, SGMO, DTIL, and INO.
- CMRX's SEC filings can be seen here. And to visit Chimerix Inc's official web site, go to www.chimerix.com.
CMRX Stock Price Chart Interactive Chart >
CMRX Price/Volume Stats
| Current price | $8.12 | 52-week high | $11.57 |
| Prev. close | $8.45 | 52-week low | $1.37 |
| Day low | $8.00 | Volume | 229,996 |
| Day high | $8.58 | Avg. volume | 1,192,815 |
| 50-day MA | $9.63 | Dividend yield | N/A |
| 200-day MA | $5.28 | Market Cap | 695.71M |
Chimerix, Inc. (CMRX) Company Bio
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. The company was founded in 2000 and is based in Durham, North Carolina.
Latest CMRX News From Around the Web
Below are the latest news stories about Chimerix Inc that investors may wish to consider to help them evaluate CMRX as an investment opportunity.
Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences ConferenceDURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days. About Chimerix Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients ... |
Insider Buying: Chimerix, Inc. (NASDAQ:CMRX) Director Acquires 1,500 Shares of StockChimerix, Inc. (NASDAQ:CMRX) Director Robert J. Meyer acquired 1,500 shares of Chimerix stock in a transaction that occurred on Monday, March 1st. The shares were purchased at an average price of $9.80 per share, for a total transaction of $14,700.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at […] |
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial - Stocks News FeedWESTON, Fla., Feb. 26, 2021 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex’s DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI),… Read More »Chimerix, Exclusive Worldwide Licensee of Cantex’s Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial |
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical TrialCantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex's DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that dociparstat sodium (DSTAT) may accelerate recovery from ALI, as well as mitigate thrombotic events in such patients. A copy of Chimerix' press release and detailed information can be found at https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-promising-topline-results-first-cohort |
Chimerix (CMRX) Q4 2020 Earnings Call TranscriptWith me on today's call are President and Chief Executive Officer Mike Sherman, Chief Medical Officer Allen Melemed, Chief Financial and Business Officer Mike Andriole, Chief Science Officer Randall Lanier, and our newest member of the team, too, Chief Interim Technology Officer Josh Allen. Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. |
CMRX Price Returns
| 1-mo | -18.80% |
| 3-mo | -1.10% |
| 6-mo | 181.94% |
| 1-year | N/A |
| 3-year | 60.47% |
| 5-year | 43.21% |
| YTD | 68.12% |
| 2020 | 137.93% |
| 2019 | -21.01% |
| 2018 | -44.49% |
| 2017 | 0.65% |
| 2016 | -48.60% |
Continue Researching CMRX
Here are a few links from around the web to help you further your research on Chimerix Inc's stock as an investment opportunity:Chimerix Inc (CMRX) Stock Price | Nasdaq
Chimerix Inc (CMRX) Stock Quote, History and News - Yahoo Finance
Chimerix Inc (CMRX) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...